Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP-Reference-Cited by-同舟云学术

Clinical features, tumor biology, and prognosis associated with MYC rearrangement and Myc overexpression in diffuse large B-cell lymphoma patients treated with rituximab-CHOP

Published:2015-11-06 Issue:12 Volume:28 Page:1555-1573
ISSN:0893-3952
Container-title:Modern Pathology
language:en
Short-container-title:Mod Pathol

Author:

Xu-Monette Zijun Y,Dabaja Bouthaina S,Wang Xiaoxiao,Tu Meifeng,Manyam Ganiraju C,Tzankov Alexander,Xia Yi,Zhang Li,Sun Ruifang,Visco Carlo,Dybkaer Karen,Yin Lihui,Chiu April,Orazi Attilio,Zu Youli,Bhagat Govind^ORCID,Richards Kristy L^ORCID,Hsi Eric D,Choi William WL,van Krieken J Han,Huh Jooryung,Ponzoni Maurilio,Ferreri Andrés JM,Møller Michael B,Parsons Ben M,Zhao Xiaoying,Winter Jane N,Piris Miguel A,McDonnell Timothy J,Miranda Roberto N,Li Yong,Medeiros L Jeffrey,Young Ken H

Publisher

Springer Science and Business Media LLC

Subject

Pathology and Forensic Medicine

Link

http://www.nature.com/articles/modpathol2015118.pdf

Reference57 articles.

1. Felsher DW . MYC inactivation elicits oncogene addiction through both tumor cell-intrinsic and host-dependent mechanisms. Genes Cancer 2010;1:597–604.

2. Delmore JE, Issa GC, Lemieux ME et al. BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 2011;146:904–917.

3. Chesi M, Matthews GM, Garbitt VM et al. Drug response in a genetically engineered mouse model of multiple myeloma is predictive of clinical efficacy. Blood 2012;120:376–385.

4. Ott G, Rosenwald A, Campo E . Understanding MYC-driven aggressive B-cell lymphomas: pathogenesis and classification. Blood 2013;122:3884–3891.

5. Kluk MJ, Chapuy B, Sinha P et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One 2012;7:e33813.

Cited by 48 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation;Nature Communications;2024-08-08

2. Molecular characterization of diffuse large B‐cell lymphomas associated with hepatitis C virus infection;British Journal of Haematology;2024-03-05

3. Navigating between Scylla and Charybdis: A roadmap to do better than Pola-RCHP in DLBCL;Cancer Treatment Reviews;2024-03

4. Myc rearrangement and concurrent high protein expression of C-Myc/Bcl2 carry an adverse prognosis in diffuse large B-cell lymphoma;Annals of Diagnostic Pathology;2023-10

5. Clinicopathologic and genetic features of the starry-sky pattern in double-expressor diffuse large B-cell lymphoma;Human Pathology;2023-09